IMS Health reports a nice increase in prescription sales from 2008 to 2009, even with a recession in full swing. That said, numbers are still well below the historic sales of a few years back, and it's anyone's guess if they will reach that high again.
Big thinker Bernard Munos delivers the goods.
Dutch pharma releases the same drug as a brand and a generic. Will this two-pronged attack work?
Proving that one good turn deserves another, Pfizer and GlaxoSmithKline announced that they would provide millions of doses of pneumonia vaccines to some of the world's most impoverished countries at massive discounts.
The number of consumers ditching their drugs at the pharmacy keeps climbing as the economy worsens.
A new report from IMS Health bumps the number of emerging markets to 17 and predicts that these nations will account for $90 billion in sales in the next four years. How will pharma take advantage of the opportunity?
NCM - Bold Brands Drive Revenue with Storytelling
Monday was a gloomy day for industry as two separate drug trials went belly up. AstraZeca's Recentin proved that it wasn't up-to-snuff compared with Avastin, and the Roche/Biogen Idec arthritis collaboration treatment, ocrelizumab, may have led to fatalities.
Three ad agencies came up with two similarly designed ways of keeping track of online healthcare conversation, harnessing the power of social media sites like Twitter and Digg.
The Indian generic firm Ranbaxy was dealt another blow this week as its version of the enlarged prostate drug Flomax was denied approval in the US just as it was about to go to market.
Improve your leadership impact
Merck’s Man in Emerging Markets
Here are five pharmaceutical advertisement parodies that will make you howl 'till it hurts.
The company released its numbers for 4Q '09, but is still hunting for more annual savings, which could come in the form of up to 15,000 job cuts.
Added funds for FDA to come from new user fees, largely for food and tobacco regulation.
The popular antidepressant is associated with up to 91 percent increase in risk of death in patients undergoing tamoxifen treatment for breast cancer.
February 10, 2010.
Gauging the Risk of Dual Enrollment - Independent Data Integrator - Clinical RSVP Whitepaper
Prix Galien 2010 Sponsorship Guide
Pfizer's strategy to use Wyeth's drug pipeline to increase its sales has paid off as the drug giant announced that its fourth quarter earnings nearly doubled year-to-year. Too bad investors are running in fear of an ugly 2010 forecast.
California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation.
Shire’s Second Act
Innovation won't happen until the industry is ready to sit down and make a big change.
All eyes are on PatientsLikeMe's new epilepsy site. The social network is backed by UCB, but the pharma firm is taking a hands-off approach. Is this the future of pharma social media?
Kalido KONA Information Appliance for Pharmaceutical Sales & Marketing Analytics - Kalido whitepaper
GlaxoSmithKline announced that it would open up its library of prospective molecules and investigational vaccines. This move gives researchers free access to study experimental treatments for illnesses that plague the world's poorest countries.
Pharma Complaint Management : Emerging Challenges and Solutions - Infosys Tech
At time when people can't even get a 3 percent cost-of-living increase, how can pharma justify price hikes pushing 500 percent (in some categories). A new study by the government's General Accountability Office examines why drug products took a massive price leap in recent years.
The push for government transparency continues with Phase I of FDA's plan to expose the inner workings of that secretive cabal known as the Food and Drug Association. First up, fancy new FAQs.
January 04. 2010.
